GE HealthCare Technologies (GEHC) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: GEHC pre-announced Q2 EPS above consensus and organic revenue growth of 3.5% (in-line with guidance), then reiterated its full-year outlook — the setup is a modest beat on profit with no incremental guidance risk, but the surprise CFO departure announced simultaneously clouds the narrative and is the single biggest swing factor for the stock on print day.

Heading into the July 29 print, the bar is manageable: consensus adjusted EPS of ~$1.04 was already reset lower after the Q1 profit guidance cut, and the July 23 pre-announcement confirmed Q2 EPS came in above that level alongside 3.5% organic revenue growth — squarely in the guided 3–4% range. Management's tone since Q1 has been one of cautious confidence — the inflation headwinds (memory chips, freight/oil, metals) are well-understood, mitigation actions (pricing on new orders, freight optimization, cost actions) are expected to build through H2, and the full-year revenue and EPS guidance range was reiterated without change. Estimate revisions have been modestly negative since Q1 — Q2 EPS consensus drifted from ~$1.05 to ~$1.04 and FY2026 EPS from ~$4.89 to ~$4.88 — but the pre-announcement has effectively de-risked the quarter, leaving the call focused on H2 cadence, Flyrcado dose trajectory, PCS strategic review progress, and Photonova Spectra pipeline conversion. The stock is down ~20% over six months, driven almost entirely by multiple compression (P/E contracted ~24% over 12 months) rather than estimate cuts, suggesting the market has already priced in significant macro uncertainty and the stock is not entering the print at a stretched valuation. The wildcard is the CFO departure: Jay Saccaro — who was the primary architect of the inflation/tariff narrative and a vocal buyer of GEHC stock post-Q1 — announced his resignation on July 21 (effective August 14), with Controller George Newcomb named interim CFO. Investor focus will be on whether management can credibly maintain H2 guidance and capital allocation commitments (buybacks, FCF) without the CFO who set them.

2. KPIs & Consensus Expectations

Key Takeaway: The Q2 bar is low and largely de-risked by the July 23 pre-announcement. Adjusted EPS (~$1.04 consensus) is the bigger swing factor given the inflation phasing narrative; revenue ($5.27B consensus) is essentially confirmed at 3.5% organic growth. The focus on the call will be H2 margin recovery cadence and Flyrcado dose trajectory.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data (Total revenues, EPS — Diluted — Operating, Revenue — PDx, Revenue — PCS, Advancing imaging solutions, Free cash flow); Q1 2026 Earnings Call transcript (guidance); July 23, 2026 pre-announcement (8-K EX-99). AIS segment reflects the combined Imaging + AVS segment restructured in Q1 2026.

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Total Revenue & Adj. EPS)

Pattern: GEHC has beaten revenue consensus in 5 of the last 8 quarters and beaten adjusted EPS consensus in 7 of the last 8 quarters — the sole EPS miss was Q1 2026, driven by a discrete PDx supplier recall and the first full quarter of inflation headwinds. Revenue beats have been modest (typically 1–2%), while EPS beats have been more variable, reflecting the company's ability to manage costs and mix. The Q2 2026 pre-announcement effectively confirms another revenue in-line and an EPS beat.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year revenue guidance is unchanged at 3–4% organic growth; profit guidance was cut at Q1 (April 29) and has not been revised since. The July 23 pre-announcement reiterated the full-year outlook in its entirety, providing a clean baseline heading into the call. The CFO departure introduces execution risk around H2 guidance credibility.

Sources: Q1 2026 Earnings Call transcript (April 29, 2026); July 23, 2026 8-K / press release (pre-announcement and CFO departure); Visible Alpha Consensus and Actuals Data (current consensus figures).

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have drifted modestly lower since Q1 earnings — Q2 EPS consensus fell ~1.2% and FY2026 EPS fell ~0.1% from the post-Q1 baseline — tracking directionally with the inflation headwind narrative but not diverging materially. The gap between consensus and guidance midpoint is narrow, suggesting the Street has largely accepted management's framework. The pre-announcement effectively locks in Q2 and shifts focus to H2 execution.

Estimates have been remarkably stable since Q1 earnings — revenue consensus is essentially flat and EPS has drifted only ~1% lower, suggesting the Street has fully digested the inflation headwind framework and is not pricing in incremental risk. The pre-announcement removes Q2 uncertainty; the call will be about whether management can credibly guide to H2 EPS acceleration (Q3+Q4 must deliver ~$3.84 combined to hit the $4.90 FY midpoint, vs. $0.99 in Q1 and ~$1.04 in Q2).

Source: Visible Alpha Consensus and Actuals Data (revision history and current consensus); Q1 2026 Earnings Call transcript (guidance); July 23, 2026 pre-announcement.

5. Stock Performance

Key Takeaway: GEHC's ~20% six-month decline is almost entirely multiple compression — P/E contracted ~24% and EV/EBITDA ~20% over 12 months — not estimate cuts, which have been minimal. The stock is not entering the print at a stretched valuation (NTM P/E ~12.8x, EV/EBITDA ~8.8x), but re-rating requires H2 execution proof and CFO transition clarity.

Current NTM Multiples (as of July 28, 2026): EV/EBITDA 8.8x | EV/Sales 1.6x | P/E 12.8x | P/FCF 14.4x | P/Sales 1.3x. The stock has de-rated sharply from 12-month-ago levels (EV/EBITDA was ~11.5x, P/E ~18.0x), reflecting investor skepticism around China, tariffs, and inflation — not fundamental deterioration. At current multiples, the stock is pricing in limited H2 recovery, creating asymmetric upside if management delivers on the back-half margin acceleration narrative.

Key Events Since Q1 Earnings (April 29, 2026): (1) May 2026: Cluster of insider open-market purchases by CEO, CFO, and multiple directors post-Q1 selloff. (2) May 11, 2026: Annual shareholder meeting — all proposals approved, new Lead Director and Committee Chair appointed. (3) July 8, 2026: GEHC announced Q2 results date (July 29). (4) July 23, 2026: Pre-announcement of Q2 EPS above consensus, 3.5% organic revenue growth, full-year guidance reiterated; CFO Jay Saccaro resignation announced simultaneously (effective August 14, 2026; George Newcomb named interim CFO).

Source: Stock performance decomposition data (NTM multiples and price/multiple change by horizon); company filings and press releases.

6. Material News & Developments

Key Takeaway: The CFO departure is the most consequential development since Q1 earnings — it introduces leadership uncertainty at a critical juncture when H2 execution and capital allocation credibility are paramount. The Q2 pre-announcement removes near-term earnings risk but shifts all attention to the call's forward narrative.

• July 23, 2026 — CFO Jay Saccaro Resignation & Q2 Pre-Announcement (8-K): Saccaro notified the board of his resignation on July 21, 2026, to pursue an opportunity outside medtech. His last day is August 14, 2026. George Newcomb (Controller and Chief Accounting Officer, age 59, GE/GEHC finance veteran since 1996) named interim CFO effective August 14, 2026; permanent search underway. Simultaneously, GEHC pre-announced Q2 EPS above consensus and organic revenue growth of 3.5% (in-line), reiterating full-year guidance. Implication: Saccaro was the primary architect of the inflation/tariff narrative and a vocal buyer of GEHC stock post-Q1. His departure creates uncertainty around H2 guidance credibility and buyback execution; investors will scrutinize Newcomb's first public appearance on the July 29 call.
• July 28, 2026 — Philips (PHG) Q2 2026 Earnings: PHG reported Q2 adjusted EBITDA margin of 16.4% (vs. ~11.9% consensus), boosted by a US tariff refund. PHG reiterated full-year comparable sales growth of 3–4.5% and raised FCF guidance to €1.5–1.7B (including tariff refund). Implication: Positive read-through for GEHC on imaging demand (PHG cited healthy North America capital investment and record order books in imaging/monitoring); PHG's tariff refund benefit is a reminder that GEHC also has potential IEEPA refund upside not in guidance.
• July 16, 2026 — Abbott (ABT) Q2 2026 Earnings: ABT reported Q2 EPS of $1.31 (vs. $1.28 consensus), raised FY2026 EPS guidance to $5.45–$5.60. Hospital lab business grew 13% YoY. CEO Ford stated healthcare demand is "durable" and procedure volumes remain stable, with Medicare covering >2/3 of US cardio device revenue. Implication: Positive read-through for GEHC on hospital capital spending and diagnostic demand; ABT's data shows no ACA-driven volume deterioration for high-acuity procedures.
• July 16, 2026 — Intuitive Surgical (ISRG) Q2 2026 Earnings: ISRG reported Q2 EPS of $2.80 (vs. $2.50 consensus), including $36M IEEPA tariff refund (+$0.08). Gross margins of 70% exceeded plan by >200 bps. US capital environment described as "stable," with system placements up 24% YoY. Maintained full-year procedure growth guidance at 13.5–15.5% (closer to midpoint). Noted continued higher input costs in freight and semiconductor memory. Implication: Positive read-through on US hospital capital stability; ISRG's freight/memory cost commentary directly mirrors GEHC's inflation headwind narrative, validating the macro backdrop.
• June 3, 2026 — Medtronic (MDT) Q4 FY2026 Earnings: MDT guided FY2027 organic revenue growth of 6.75–7.25% and non-GAAP EPS of $5.90–$6.00 (+6.7–8.5%). Tariffs impacted Q4 non-GAAP operating margin by 80 bps and full-year by 50 bps; FY2027 guidance explicitly includes tariff impacts. Implication: Broad medtech demand environment remains healthy; tariff headwinds are an industry-wide phenomenon, not GEHC-specific.
• May 11, 2026 — Annual Shareholder Meeting (8-K): All proposals approved; new Lead Director and Committee Chair appointed. No material governance changes.
• April 30 – May 26, 2026 — Cluster of Insider Open-Market Purchases: CEO Arduini (4,169 shares, Apr 30), CFO Saccaro (3,310 shares, May 1), Director Jimenez (1,750 shares, Apr 30), Director Culp (80,805 shares, May 6), Director Stromberg (1,000 shares, May 6), Director Yang Watkin (1,000 shares, May 8), Director Hochman (1,618 shares, May 12), Director Lobo (10,000 shares, May 22) — all open-market purchases following the post-Q1 selloff. Implication: Unusually broad insider conviction signal; CFO explicitly cited intrinsic value DCF showing shares at a substantial discount to intrinsic value.

7. Insider Transaction Activity

Key Takeaway: The post-Q1 insider buying cluster is one of the most notable conviction signals in GEHC's short public history — CEO, CFO, and five directors all purchased shares in the open market within days of the post-earnings selloff. No insider sales have been filed in the period. The CFO's subsequent resignation (July 21) adds a layer of complexity to interpreting his May 1 purchase.

No insider sales were filed in the period. All transactions are open-market purchases (Form 4, transaction code P). No 10b5-1 plan initiations were disclosed in connection with these purchases. The CFO's May 1 purchase is notable in retrospect given his July 21 resignation; however, the purchase was made ~11 weeks before the resignation notice and was explicitly framed as a conviction buy based on intrinsic value analysis.

Source: SEC Form 4 filings (Insider Transaction Data).

8. Peer Commentary & Read-Through

Key Takeaway: Peer commentary from PHG, ISRG, ABT, and MDT — all reporting in the last 60 days — is broadly constructive for GEHC's Q2 setup and H2 outlook: North America hospital capital spending is stable-to-healthy, diagnostic demand is durable, and tariff/freight/memory cost headwinds are an industry-wide phenomenon (not GEHC-specific). China remains the shared weak spot. Only forward-looking commentary about the current and upcoming periods is included below; retrospective Q-over-Q commentary has been excluded.

Note on scope: All commentary below is drawn from peer earnings calls and releases for periods that reported during or after GEHC's Q1 2026 earnings (April 29, 2026). Only forward-looking statements about calendar Q2 2026 onward (i.e., the current GEHC reporting quarter and beyond) are included. Retrospective commentary about peers' own prior-quarter results is excluded.

8.1 Philips (PHG) — Q2 2026 Earnings Call (July 28, 2026)

Relevance to GEHC: PHG is GEHC's closest direct peer — both compete in diagnostic imaging (CT, MRI, ultrasound), patient monitoring, and image-guided therapy. PHG's forward guidance and market commentary are the highest-quality read-through available.

Limitations: PHG also has a Personal Health segment (consumer electronics) not comparable to GEHC. PHG's specific product wins, margin structure, and geographic mix differ. PHG received a one-time US tariff refund in Q2 that boosted margins; GEHC has not yet recognized a similar benefit.

• Hospital Capital & Imaging Demand (Forward-Looking): PHG cited "healthy patient volumes, procedural growth, and sustained capital investment by larger health systems" in North America as ongoing demand drivers. PHG has "record order books in some of our high margin businesses, like IG [image-guided therapy] and monitoring." PHG expects Precision Diagnosis (CT, MRI, ultrasound) to return to positive sales growth in H2 2026, with double-digit order growth outside China. → GEHC read-through: Supports GEHC's AIS segment demand outlook and book-to-bill trajectory.
• China (Forward-Looking): PHG expects China to be "broadly stable overall" for the full year, with strength in personal health offsetting "continued weakness in health systems." Centralized procurement expansion is creating "turmoil in the market" and margin pressure for undifferentiated technology. PHG is pursuing a "selective go-to-market approach" focused on unique innovations. Q3 2026 comparable sales growth expected "at the lower end of our full year range due to China and ultrasound." → GEHC read-through: Consistent with GEHC's cautious China outlook; PHG's Q3 China warning is a mild negative read-through for GEHC's China segment in Q3.
• Cost Inflation & Tariffs (Forward-Looking): PHG expects "high single-digit cost inflation for the full year 2026," with a greater impact in H2 as higher-cost inventory rolls through P&L. Freight costs are "significantly increasing" due to Middle East tensions, with no hedges in place — these costs will "roll over into 2027." PHG's outlook incorporates "currently known tariffs, including those announced on July 23." Mitigation benefits expected to increase in H2. → GEHC read-through: Directly validates GEHC's inflation narrative (freight/memory). PHG's unhedged freight exposure rolling into 2027 is a cautionary signal for GEHC's own 2027 cost outlook.
• Order Conversion Times (Forward-Looking): PHG noted longer order-to-revenue conversion times due to "larger deals and more complex implementation" and constrained installation capacity in the market. Order intake expected to "return to mid-single digit range in Q3 and beyond." → GEHC read-through: Consistent with GEHC's own 5–6 month order-to-revenue cycle; longer conversion times could delay backlog monetization for both companies.
• Tariff Refund Upside (Forward-Looking): PHG recognized a US tariff refund in Q2 that boosted adjusted EBITDA margin to 16.4% (vs. ~11.9% consensus). PHG raised FCF guidance to €1.5–1.7B including the refund. → GEHC read-through: GEHC management stated on the Q1 call that IEEPA tariff refunds are "not included in the forecast." If GEHC receives a similar refund, it would represent unguided upside to H2 EPS and FCF.

8.2 Intuitive Surgical (ISRG) — Q2 2026 Earnings Call (July 16, 2026)

Relevance to GEHC: ISRG is a bellwether for US hospital capital spending and procedure volumes. Its commentary on the US capital environment, ACA subsidy impacts, and input cost inflation (freight, semiconductor memory) is directly relevant to GEHC's imaging capital equipment demand and cost structure.

Limitations: ISRG's business is highly concentrated in robotic-assisted surgery — a niche with dominant market position and different pricing dynamics than GEHC's diversified imaging/diagnostics portfolio. ISRG's specific procedure trends (bariatric, GLP-1 impact) are not directly transferable.

• US Hospital Capital Environment (Forward-Looking): ISRG described the US capital environment as "stable for some time now," evidenced by 24% YoY growth in US system placements in Q2. Capital pipeline described as "healthy," driven by DaVinci 5 demand. ~70% of US systems are under leasing arrangements, providing flexibility for capital-constrained customers. Some customers express caution over ACA enrollment trends, but this has "not yet impacted our pipeline." → GEHC read-through: Positive signal for GEHC's AIS segment capital equipment demand in Q2 and Q3; leasing flexibility trend is consistent with GEHC's own financing programs.
• Procedure Volumes & ACA Impact (Forward-Looking): ISRG maintained full-year 2026 Da Vinci procedure growth guidance at 13.5–15.5%, expecting to be "closer to the midpoint." Observed a "modest adverse impact" to Q2 US procedure growth from ACA premium subsidy expiration, with a "slight moderation" in deferrable benign procedures starting Q1. US bariatric cases declined high-single digits due to GLP-1 usage. ISRG will "watch US procedure trends carefully in coming quarters." Q3 has a tougher YoY comp in the US. → GEHC read-through: Mild negative read-through for elective/deferrable procedure volumes in Q3; however, GEHC's imaging demand is more tied to capital budgets and non-deferrable diagnostic needs than to elective surgical volumes.
• Input Cost Inflation (Forward-Looking): ISRG continues to expect "higher input costs in certain areas, including freight and semiconductor memory" for the remainder of 2026. ISRG received a $36M IEEPA tariff refund in Q2 (+$0.08 EPS); excluding this, Q2 non-GAAP gross margin would have been 68.7%. → GEHC read-through: Direct validation of GEHC's freight and memory chip inflation narrative. ISRG's tariff refund is a reminder that GEHC's guidance conservatively excludes any IEEPA refund benefit.
• China Capital Environment (Forward-Looking): China remains "competitive and challenging from a pricing perspective" with lower tender activity and increased domestic competition. ISRG is engaging with provincial governments on charge code policy and progressing through the green channel for SP and DaVinci 5. Centralized procurement is expected to "structurally develop tenders" to reinforce strong robotic programs rather than replicate pharmaceutical VBP. → GEHC read-through: Consistent with GEHC's cautious China outlook; centralized procurement dynamics are a shared headwind across imaging and surgical equipment.
• International Capital (Forward-Looking): Japan: new reimbursement decisions effective June 1 viewed positively; "cautious tone of optimism" for the future. Europe: mixed — some markets stressed by government budgets, others healthy. XIR systems (cost-sensitive markets, ASCs) expected to be a "significant part of placements over coming quarters." → GEHC read-through: Japan reimbursement improvement is a mild positive for GEHC's APAC imaging demand; European government budget pressure is a shared headwind.

8.3 Abbott Laboratories (ABT) — Q2 2026 Earnings Call (July 16, 2026)

Relevance to GEHC: ABT's diagnostics business (hospital labs, cancer diagnostics) and its commentary on US healthcare demand, procedure volumes, and China VBP dynamics are relevant read-throughs for GEHC's PDx and AIS segments.

Limitations: ABT's portfolio is highly diversified (nutrition, established pharma, CGM) and its diagnostics business focuses on lab tests and point-of-care rather than large capital imaging equipment. ABT's specific product launches and pipeline are not transferable to GEHC.

• Healthcare Demand & Procedure Volumes (Forward-Looking): ABT CEO Ford stated that diagnostic test volume data from instruments globally "continues to reflect strong and stable demand for testing" — a "positive indication of the durable underlying demand for healthcare, not just in the US but globally." Hospital lab business grew 13% in Q2. Ford stated demand for "high acuity life-saving products is very inelastic" and that Medicare covers >2/3 of US cardio device revenue, insulating the business from ACA subsidy changes. Ford: "I continue to believe that healthcare demand is just going to continue to accelerate" driven by aging demographics (10,000 Americans turn 65 every day). → GEHC read-through: Strongly positive for GEHC's imaging and PDx demand; durable diagnostic demand and hospital lab strength support GEHC's AIS and PDx revenue outlook.
• Cancer Diagnostics Demand (Forward-Looking): ABT expects cancer diagnostics growth in H2 2026 to be "higher than the first half," supported by increasing volumes from care gap programs and continued international adoption. Care gap programs (helping health systems achieve quality ratings) "tend to happen in the second half." → GEHC read-through: Positive for GEHC's PDx segment (Flyrcado, PET/SPECT) — cancer diagnostics demand acceleration in H2 is consistent with GEHC's own Flyrcado ramp narrative.
• China VBP Dynamics (Forward-Looking): ABT is "still forecasting a decline in the China business, but much, much lower — mid-single digits" in H2 2026, vs. a ~30% decline over the prior five quarters. VBP impact is "subsiding a little bit." → GEHC read-through: Mild positive — ABT's China stabilization narrative is consistent with GEHC's own "green shoots" commentary; both companies expect China to remain a headwind but at a diminishing rate.
• H2 Acceleration Confidence (Forward-Looking): ABT CEO expressed "high confidence" in H2 acceleration, citing "clear line of sight to key drivers" including nutrition, electrophysiology, core lab, and cancer diagnostics. ABT raised FY2026 EPS guidance to $5.45–$5.60 and the stock rose 14% on earnings day (largest single-day gain since 2002). → GEHC read-through: Positive sentiment signal for the broader medtech sector; ABT's H2 confidence and guidance raise demonstrate that the macro environment is not uniformly negative.

8.4 Medtronic (MDT) — Q4 FY2026 Earnings (June 3, 2026)

Relevance to GEHC: MDT's FY2027 guidance (covering calendar Q2 2026 through Q1 2027) and its commentary on tariff impacts and hospital capital spending provide a broad medtech sector read-through. MDT's CFO stated the company is entering FY2027 with "strong momentum, a resilient operating foundation, and a clear path to deliver durable growth."

Limitations: MDT's product portfolio (cardiac devices, surgical robotics, insulin pumps, surgical tools) differs significantly from GEHC's imaging/diagnostics focus. MDT's FY2027 guidance includes a 53rd-week benefit and full-year Diabetes consolidation that are not applicable to GEHC. MDT did not provide specific commentary on imaging demand or hospital capital spending for imaging equipment.

• Medtech Demand Environment (Forward-Looking): MDT guided FY2027 organic revenue growth of 6.75–7.25%, reflecting broad-based demand across cardiac, surgical, and neuroscience segments. CEO Martha highlighted "building momentum in highest growth opportunities" including surgical robotics and neurostimulation. → GEHC read-through: Positive macro signal — broad medtech demand remains healthy heading into calendar H2 2026.
• Tariff Impacts (Forward-Looking): MDT's FY2027 non-GAAP EPS guidance of $5.90–$6.00 explicitly includes "impacts from tariffs," indicating tariff headwinds are expected to persist into the current fiscal year. Q4 FY2026 non-GAAP operating margin included 80 bps of tariff impact; full-year FY2026 was 50 bps. → GEHC read-through: Validates that tariff headwinds are an industry-wide, multi-year phenomenon — not a GEHC-specific issue. MDT's ability to guide to 6.7–8.5% EPS growth despite tariffs is a positive precedent for GEHC's own mitigation narrative.
• Innovation Pipeline as Growth Driver (Forward-Looking): MDT highlighted a "uniquely robust pipeline" with tuck-in M&A and investment strategy as key drivers of durable growth. Recent FDA clearances (Stealth AXiS, ProGrip Advanced) and pending submissions (Hugo RAS for general surgery) indicate ongoing capital equipment innovation. → GEHC read-through: Consistent with GEHC's own new product cycle thesis (Photonova Spectra, Freelium MR, next-gen SPECT); innovation-driven capital equipment demand is a shared growth lever.

8.5 Peer Read-Through Summary

9. Key Questions for the Q2 2026 Earnings Call

The following are the highest-priority topics investors and analysts are likely to probe on the July 29 call:

1. CFO Transition: What is the timeline for a permanent CFO search? How will George Newcomb's interim role affect capital allocation decisions (buybacks, M&A)? Can management credibly commit to the H2 EPS acceleration narrative without the CFO who set it?
2. H2 Margin Recovery Cadence: Q1 + Q2 combined EPS is ~$2.03; the FY midpoint of $4.90 requires ~$2.87 in H2. What specific pricing actions, freight optimization, and cost measures are now in the run rate? How much of the $250M gross inflation impact has been offset?
3. Flyrcado Dose Trajectory: Management committed to providing a weekly dose data point in July. What is the current weekly dose run rate? Is the $500M+ by 2028 target still intact? How is the radiopharmacy learning curve progressing?
4. PCS Strategic Review: Has the strategic portfolio assessment of PCS progressed? Are divestitures or partnerships being actively explored? What is the timeline for a decision?
5. Photonova Spectra Pipeline: How large is the commercial pipeline funnel (management previously cited >$100M)? When does the first revenue conversion occur? Is the H1 2027 revenue contribution timeline still intact?
6. IEEPA Tariff Refund: Has GEHC submitted for IEEPA tariff refunds? What is the potential magnitude? When could it be recognized? (PHG and ISRG both recognized refunds in Q2.)
7. China Outlook: Did China improve sequentially in Q2 as expected? Are the "green shoots" from Q1 (improving market predictability, Sinopharm JV traction) continuing? Is the full-year China decline still tracking to plan?
8. Share Buyback Activity: CFO Saccaro explicitly signaled continued buyback activity in Q2 on the Jefferies conference call. What was the Q2 repurchase volume and average price? What is the remaining authorization?

Disclosures & Sources: This document is prepared for informational purposes only. All financial data sourced from Visible Alpha Consensus and Actuals Data, SEC filings (Form 4, 8-K), company earnings call transcripts, and press releases as cited throughout. Consensus estimates as of July 28, 2026. Insider transaction data from SEC Form 4 filings. Peer commentary sourced from PHG Q2 2026 earnings call (July 28, 2026), ISRG Q2 2026 earnings call (July 16, 2026), ABT Q2 2026 earnings call (July 16, 2026), and MDT Q4 FY2026 earnings release (June 3, 2026).